AstraZeneca Ultomiris gets USFDA approval for adults with neuromyelitis optica spectrum disorder Ruchika Sharma26 March 2024 12:52 PM ISTUltomiris, a long-acting C5 complement inhibitor, provides immediate, complete and sustained complement inhibition.
Conduct India-specific Trial: CDSCO Panel Tells Roche on Satralizumab to Treat neuromyelitisoptica spectrum disorders Dr. Divya Colin8 Feb 2024 6:00 PM ISTNew Delhi: With an aim to establish the safety and efficacy of the Monoclonal Antibody Satralizumab in Indian patients, the Subject Expert Committee...
AstraZeneca Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder Ruchika Sharma22 Oct 2023 4:00 PM ISTCambridge: AstraZeneca has announced that Soliris (eculizumab) has been approved in China for the treatment of adult patients with neuromyelitis...
Enhance risk evaluation for Rare Inflammatory Disease drug: USFDA asks AstraZeneca Ruchika Sharma6 Sept 2023 2:30 PM ISTCambridge: The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License...
AstraZeneca Ultomiris gets Japanese nod for prevention of relapses in patients with neuromyelitis optica spectrum disorder Ruchika Sharma28 May 2023 11:00 AM ISTNMOSD is a rare and debilitating autoimmune disease that affects the central nervous system, including the spine and optic nerves.
AtraZeneca's Ultomiris approved in EU for adults with neuromyelitis optica spectrum disorder Ruchika Sharma12 May 2023 1:30 PM ISTNeuromyelitis optica spectrum disorder is a rare and debilitating autoimmune disease that affects the central nervous system including the spine and...
AstraZeneca Ultomiris recommended for marketing approval in EU for neuromyelitis optica spectrum disorder Ruchika Sharma4 April 2023 4:00 PM ISTNMOSD is a rare and debilitating autoimmune disease that affects the central nervous system, including the spine and optic nerves.
FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord Hina Zahid18 Aug 2020 8:00 AM ISTThe U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in...
FDA approves Ineblizumab for rare autoimmune disease of CNS Dr. Kamal Kant Kohli12 Jun 2020 4:33 AM ISTThe US Food and Drug Administration (FDA) has approved inebilizumab-cdon injection (Uplizna) for treatment of neuromyelitis optica spectrum disorder...
